Serum phosphorus fell to similar levels in two-thirds of peritoneal dialysis patients, but sucroferric oxyhdroxide recipients had a lower pill burden. The iron-based phosphate binder sucroferric ...
Oct 22 (Reuters) - Genzyme Corp said U.S. health regulators approved its phosphate binder, Renvela, for patients with chronic kidney disease on dialysis. The biotechnology company also plans to apply ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results